The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
PLK1, A Potential Target for Cancer Therapy
Open accessAbstract
Polo-like kinase 1 (PLK1) plays an important role in the initiation, maintenance, and completion of mitosis. Dysfunction of PLK1 may promote cancerous transformation and drive its progression. PLK1 overexpression has been found in a variety of human cancers and was associated with poor prognoses in cancers. Many studies have showed that inhibition of PLK1 could lead to death of cancer cells by interfering with multiple stages of mitosis. Thus, PLK1 is expected to be a potential target for cancer therapy. In this article, we examined PLK1's structural characteristics, its regulatory roles in cell mitosis, PLK1 expression, and its association with survival prognoses of cancer patients in a wide variety of cancer types, PLK1 interaction networks, and PLK1 inhibitors under investigation. Finally, we discussed the key issues in the development of PLK1-targeted cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
BioGRID: a general repository for interaction datasets
Stark, C. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj109 · Cited by 3,960
BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo
Steegmaier, M., Hoffmann, M., Baum, A., Lénárt, P., Petronczki, M., Krššák, M., Gürtler, U., Garin-Chesa, P., Lieb, S., Quant, J., et al. (2007) · Current Biology · doi:10.1016/j.cub.2006.12.037 · Cited by 834
Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery
Macůrek, L., Lindqvist, A., Lim, D., Lampson, M. A., Klompmaker, R., Freire, R., Clouin, C., Taylor, S. S., Yaffe, M. B., & Medema, R. H. (2008) · Nature · doi:10.1038/nature07185 · Cited by 710
Mechanisms of Multidrug Resistance in Cancer
Gillet, J.-P., & Gottesman, M. M. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-416-6_4 · Cited by 685
Shared and separate functions of polo-like kinases and aurora kinases in cancer
Lens, S. M. A., Voest, E. E., & Medema, R. H. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2964 · Cited by 597
Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics
Gutteridge, R. E. A., Ndiaye, M. A., Liu, X., & Ahmad, N. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0897 · Cited by 406
Rudolph, D., Steegmaier, M., Hoffmann, M., Grauert, M., Baum, A., Quant, J., Haslinger, C., Garin-Chesa, P., & Adolf, G. R. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2445 · Cited by 398
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent
Gumireddy, K., Reddy, M. V. R., Cosenza, S. C., Nathan, R. B., Baker, S. J., Papathi, N., Jiang, J., Holland, J., & Reddy, E. P. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.009 · Cited by 367
Cited by
Mechanisms of Taxane Resistance
Maloney, S., Spring, C., Morejon-Lasso, L., & Prosperi, J. (2020) · Cancers · doi:10.3390/cancers12113323 · Cited by 198
Present and Future Perspective on PLK1 Inhibition in Cancer Treatment
Chiappa, M., Petrella, S., Damia, G., Broggini, M., Guffanti, F., & Ricci, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.903016 · Cited by 120
Feng, L., Wang, G., Chen, Y., He, G., Liu, B., Liu, J., Chiang, C., & Ouyang, L. (2022) · Medicinal Research Reviews · doi:10.1002/med.21859 · Cited by 65
Cyclers’ kinases in cell division: from molecules to cancer therapy
Milletti, G., Colicchia, V., & Cecconi, F. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01196-z · Cited by 39
Selective Wee1 degradation by PROTAC degraders recruiting VHL and CRBN E3 ubiquitin ligases
Aublette, M. C., Harrison, T. A., Thorpe, E. J., & Gadd, M. S. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128636 · Cited by 35
Metadata
- Authors
- Liu, Z., Sun, Q., & Wang, X.
- Venue
- Translational Oncology
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 10
- Issue
- 1
- Pages
- 22-32
- ISSN
- 1936-5233 (ISSN-L)
- OpenAlex
- W2549761003
- Cited by
- 454
- References
- 119
- FWCI
- 14.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PLK1, A Potential Target for Cancer Therapy. https://app.cochat.ai/papers/10.1016/j.tranon.2016.10.003
- The paper
- Liu, Z., Sun, Q., & Wang, X. (2017). PLK1, A Potential Target for Cancer Therapy. Translational Oncology. https://doi.org/10.1016/j.tranon.2016.10.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.